These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28368440)

  • 1. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study.
    Kataoka Y; Ebi N; Fujimoto D; Hara S; Hirano K; Narabayashi T; Tanaka T; Tomii K; Yoshioka H
    Ann Oncol; 2017 Jun; 28(6):1402. PubMed ID: 28368440
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
    Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Int J Clin Oncol; 2017 Aug; 22(4):690-697. PubMed ID: 28382561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Gyawali B; Ota A; Ando Y
    N Engl J Med; 2016 Feb; 374(5):493. PubMed ID: 26840146
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Hasegawa T; Uno H; Wei LJ
    N Engl J Med; 2016 Feb; 374(5):492-3. PubMed ID: 26840145
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H; Brahmer J
    N Engl J Med; 2016 Feb; 374(5):493-4. PubMed ID: 26840144
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
    Yoshida T; Furuta H; Hida T
    Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case series of pleomorphic carcinomas of the lung treated with nivolumab.
    Kanazu M; Uenami T; Yano Y; Nakatsubo S; Hosono Y; Ishijima M; Akazawa Y; Yamaguchi T; Urasaki K; Mori M; Yokota S
    Thorac Cancer; 2017 Nov; 8(6):724-728. PubMed ID: 28881488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer.
    Furuta H; Yoshida T; Shimizu J; Tomita N; Yatabe Y; Hida T
    J Thorac Oncol; 2017 Nov; 12(11):1733-1736. PubMed ID: 28774862
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab for advanced squamous cell lung cancer: what are the next steps?
    de Mello RA; Pousa I; Pereira D
    Lancet Oncol; 2015 Mar; 16(3):234-5. PubMed ID: 25704436
    [No Abstract]   [Full Text] [Related]  

  • 10. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab--an effective second-line treatment for NSCLC.
    Romero D
    Nat Rev Clin Oncol; 2015 Dec; 12(12):685. PubMed ID: 26483299
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.
    Tamiya M; Tamiya A; Inoue T; Kimura M; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Imamura F
    PLoS One; 2018; 13(2):e0192227. PubMed ID: 29470536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
    Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
    Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
    Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
    Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nivolumab, a new hope in non-small cell lung cancer].
    Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
    Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Curioni-Fontecedro A; Ickenberg C; Franzen D; Rogler G; Burger IA; van den Broek M
    Ann Oncol; 2017 Aug; 28(8):2040-2041. PubMed ID: 28838208
    [No Abstract]   [Full Text] [Related]  

  • 20. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
    J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.